We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current LABU market cap is 1.39B. The company's latest EPS is USD -59.9614 and P/E is -28.95.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End October 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 8.92M | 2.29M | 798k | 5.28M | 19.25M |
| Operating Income | 0 | 0 | 0 | 0 | 0 |
| Net Income | -62.55M | 338.3M | -86.32M | -1.36B | -746.28M |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End October 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 569.37M | 420.23M | 846.21M | 1.37B | 917.6M |
| Total Liabilities | 81.91M | 127.93M | 73.41M | 208.46M | 240.1M |
| Total Equity | 487.45M | 292.3M | 772.8M | 1.16B | 677.51M |
| Market Cap | 1.39B |
| Price to Earnings Ratio | -28.95 |
| Price to Sales Ratio | 1.12k |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 31.89 |
| Dividend Yield | - |
| Shares Outstanding | 12.45M |
| Average Volume (1 week) | 2.41M |
| Average Volume (1 Month) | 2.45M |
| 52 Week Change | -16.99% |
| 52 Week High | 176.9899 |
| 52 Week Low | 48.402 |
| Spread (Intraday) | 0.21 (0.19%) |
| Company Name | Direxion Daily S&P Biotech Bull 3X Shares New |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https:// |
| Industry | mgmt invt offices, open-end (6722) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
